Navigation Links
ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohn's Disease
Date:6/12/2008

hn's Disease

Crohn's disease is a chronic inflammatory condition of the gastrointestinal tract. It is estimated that the disease affects over 500,000 patients in Europe and North America. Patients suffer periods of flare-ups characterized by intense symptoms, interspersed with periods of relative remission where symptoms decrease or disappear. As Crohn's disease is a chronic condition, patients continue on a given therapeutic regimen from the time of diagnosis over the course of a lifetime, layering additional therapies as flare-ups recur or persist in an effort to reduce symptoms. When medications can no longer control symptoms, patients have few options beyond surgery.

About ChemoCentryx

ChemoCentryx, Inc., is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a network of secreted chemokine molecules, or ligands, and cell surface receptors that regulates inflammation. Based on its proprietary drug discovery and drug development platform, ChemoCentryx has internally generated several clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds. ChemoCentryx's lead compound, Traficet-EN, a specific CCR9 antagonist, is currently in a Phase II/III multi-national clinical trial, called PROTECT-1, in patients with moderate-to-severe Crohn's disease. Additional programs include the clinical development of CCX140, which targets the CCR2 receptor, currently in a Phase I clinical trial and intended for subsequent development to treat diseases such as vascular restenosis, Type 2 diabetes and/or multiple sclerosis; and CCX354, a CCR1 antagonist currently in a Phase I clinical trial, being developed for inflammatory diseases such as rheumatoid a
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
7. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
8. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
9. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)...  Sage Analytics ( www.sageanalytics.com ), the developers of ... systems, announced its sponsorship of the California Cannabis Industry ... number of tickets are available for groups or individuals ... while enjoying an open bar, buffet dinner and hors ... Bay at sunset. With the legislative session ...
(Date:8/3/2015)...  Depomed, Inc. (NASDAQ: DEPO ) ("Depomed" or ... HZNP ) ("Horizon") announcement that it intends to ... a record date to determine the shareholders eligible to ... Board will review the request when it is received. ... the information required under Depomed,s bylaws, the Depomed Board ...
(Date:8/3/2015)... , August 3, 2015 ... by Persistence Market Research "Global Market Study on ... to Witness Highest Growth by 2022", the global physiotherapy ... Bn by the end of 2015 and is expected ... 2015 to 2022, to account for US$23.7 Bn by ...
Breaking Medicine Technology:Sage Analytics Sponsors California Cannabis Industry Association Bay Area Cruise FUNdraiser 2Depomed Comments on Horizon Pharma Announcement 2Depomed Comments on Horizon Pharma Announcement 3Depomed Comments on Horizon Pharma Announcement 4Depomed Comments on Horizon Pharma Announcement 5Depomed Comments on Horizon Pharma Announcement 6Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 2Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 3Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 4
... Aug. 24 GE Healthcare is proud to ... is now included in the company,s ecomagination(SM) campaign. ... contrast media, offers significant advantages over traditional glass ... healthcare workers who administer contrast media to patients, ...
... Aug. 24 Regenicin, Inc. ... biotechnology company, announced today that Dr. Joseph Rubinfeld, one of ... agreed to join the company,s board of directors. Dr. Rubinfeld ... PermaDerm™, Regenicin,s proprietary autologous cultured skin ...
Cached Medicine Technology:+PLUSPAK (polymer bottle) Packaging Receives GE's Distinguished ecomagination(SM) Approval 2+PLUSPAK (polymer bottle) Packaging Receives GE's Distinguished ecomagination(SM) Approval 3Regenicin Appoints Amgen Co-founder Dr. Joseph Rubinfeld to Board of Directors 2
(Date:8/3/2015)... ... August 03, 2015 , ... Representatives with Health Food ... its website. , “Our ‘Ask a Nutritionist’ feature on our website is a free ... said Liza Brisk, nutritionist and spokeswoman for Health Food Grocers. , Health Food Grocers’ ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... Journal Constitution, the new Lifetime reality series, “Atlanta Plastic” is getting attention for ... receives plastic surgery, with its predominantly African-American cast of doctors and patients. Beverly ...
(Date:8/3/2015)... , ... August 03, 2015 , ... ... of Appeals ruled in favor of the firm’s client Rebecca Hamsher, deciding that ... Medical Center must reimburse benefits for Hamsher’s residential treatment for bulimia, depression and ...
(Date:8/3/2015)... ... August 03, 2015 , ... Novation, the ... to offer pharmacogenetic lab testing and precision medicine solutions that can help pharmacists ... , Annually, more than 8.6 million adverse drug events are reported in the ...
(Date:8/3/2015)... CA (PRWEB) , ... August 03, 2015 , ... ... services to help patients in need. Most people know that general health emergencies, such ... Unfortunately, a fewer amount of people know where to turn to during a dental ...
Breaking Medicine News(10 mins):Health News:Health Food Grocers Launches "Ask a Nutritionist" Service 2Health News:Health Food Grocers Launches "Ask a Nutritionist" Service 3Health News:Article on Lifetime’s New “Atlanta Plastic” Reality Series Underlines the Diversity of Today’s Plastic Surgery Patients, Says Plastic Surgeon Dr. J 2Health News:Article on Lifetime’s New “Atlanta Plastic” Reality Series Underlines the Diversity of Today’s Plastic Surgery Patients, Says Plastic Surgeon Dr. J 3Health News:Kantor & Kantor Announces North Cypress Medical Center Must Reimburse Benefits for Mental Health Treatment 2Health News:Kantor & Kantor Announces North Cypress Medical Center Must Reimburse Benefits for Mental Health Treatment 3Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 2Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 3Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 2Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 3
... ... with HCG Diet Drops , ... 14, 2010 -- It is no secret that obesity has reached epidemic proportions in our country. ... as a result of the extra pounds. , , ,But thanks to the HCG ...
... ... accident claims service National Accident Helpline warns of the dangers of cycling injuries and urges caution ... (PRWEB) June 14, ... to prevent cycling injuries now the improving weather is seeing an increasing number of people take ...
... ... the amazing true tale of one man,s journey of growing up in poverty ... a college degree. He decided to make a difference in the lives ... numerous local and national awards for his community work. He took his ...
... ... software is pleased to welcome Click2Scan Ltd. a document scanning specialist, and document management software ... ... Ltd. www.click2scan.co.uk with offices in Wiltshire and London is one of the fastest ...
... ... Jazz Festival, , ... Newport, R.I. (PRWEB) June 14, 2010 -- New Festival Productions today announced that discounted ... the 2010 CareFusion Newport Jazz Festival in Newport, RI, August 6-8. Generously donated by ...
... ... in cosmetic, facial plastic, and reconstructive surgery, understands that women need options. With an ... an alternative method to breast implant surgery. Natural breast augmentation allows patients the opportunity ... ...
Cached Medicine News:Health News:Thousands Drop The Weight For Good with HCG Diet Drops 2Health News:Break The Injury Cycle, Says National Accident Helpline 2Health News:Celebrated Father Overcame Poverty and Mental Illness to Help His Son Earn a Scholarship to Harvard 2Health News:FileHold Document Management Software welcomes Click2ScanLtd. as a Value Added Re-sellers in the UK 2Health News:CareFusion Newport Jazz Festival Discounts Tickets for Health Care Practitioners 2Health News:Del Mar Plastic Surgeon Dr. Maurice Sherman Now Offering Natural Breast Implant Alternatives 2
Prognosis / Patient Management. HIV-1 Viral Load Assay. NucliSens HIV-1 QT covers the entire dynamic range of viral load testing from a single patient sample, without reflex testing or thermalcycli...
EIA for Donor Screening. Synthetic peptide Enzyme Immunoassay (EIA) for the detection of antibodies to Human Immunodeficiency Virus Types 1 and/or 2,(HIV-1 and HIV-2) in human serum, plasma or ca...
... OraQuick ADVANCE Rapid HIV-1/2 ... single-use, qualitative immunoassay to ... Immunodeficiency Virus Type 1 ... (HIV-2) in oral fluid, ...
... performance benefits of TiMAX material have been applied ... Greater strength and an ultra-low profile combine to ... the lower extremity. , ,This complete set of ... Plate , Fibula Composite Plate ...
Medicine Products: